Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 10.36 Second Amendment to Secured Credit Agreement with Aipharma Global Holdings LLC Dated October 27, 2021
- 10.42 Form of Warrant Reduction and Release Agreement Dated As of November 24, 2021
- 10.43 First Amendment to Transaction Agreement Dated December 1, 2021, by and Between the Company and Aipharma Global Holdings LLC
- 10.44 Third Amendment to Secured Credit Agreement Dated December 1, 2021, by and Among Aipharma, Aipharma Holdings Limited, Aipharma Asia Limited and the Company
- 10.45 Second Amendment to Transaction Agreement Dated December 7, 2021, by and Between the Company and Aipharma Global Holdings LLC
- 10.46 Secured Credit Agreement, Dated As of December 8, 2021, by and Among the Company and the Target Company
- 10.47 Third Amendment to Transaction Agreement Dated December 17, 2021, by and Between the Company and Aipharma Global Holdings LLC
- 10.48 Fifth Amendment to Secured Credit Agreement Dated December 22, 2021, by and Among Aipharma, Aipharma Holdings Limited, Aipharma Asia Limited and the Company
- 10.49 Sixth Amendment to Secured Credit Agreement Dated December 28, 2021, by and Among Aipharma, Aipharma Holdings Limited, Aipharma Asia Limited and the Company
- 10.50 Employment Agreement, Dated As of January 28, 2022 Between Aditxt, Inc. and Matthew Shatzkes, Chief Legal Officer and General Counsel
- 10.51 Forbearance Agreement and Seventh Amendment to Secured Credit Agreement Dated As of February 14, 2022 by and Among the Company, Cellvera Global Holdings LLC, Cellvera Holdings LTD., Cellvera Asia Limited
- 10.52 Fourth Amendment to Transaction Agreement Dated December 22,2021, by and Between the Company and Aipharma Global Holdings LLC
- 23.1 Consent of Dbbmckennon, Independent Registered Public Accounting Firm
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- Download Excel data file
- View Excel data file
ADTX similar filings
Filing view
External links
EXHIBIT 32.1
CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350,
AS ENACTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Aditxt, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Amro Albanna, Chief Executive Officer of the Company and Thomas J. Farley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
March 31, 2022 | /s/ Amro Albanna |
Amro Albanna | |
Chief Executive Officer | |
(Principal Executive Officer) | |
March 31, 2022 | /s/ Thomas J. Farley |
Thomas J. Farley | |
Chief Financial Officer | |
(Principal Financial and Accounting Officer) |